Johnson & Johnson (JNJ) Non Operating Income (2009 - 2026)
Johnson & Johnson (JNJ) posted Non Operating Income of -$294.0 million for Q1 2026, up 39.13% sequentially from -$483.0 million in Q4 2025, and down 104.02% YoY from $7.3 billion in Q1 2025.
Johnson & Johnson (JNJ) Non Operating Income (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Non Operating Income data on file, last reported at -$294.0 million in Q1 2026.
- Quarterly Non Operating Income fell 104.02% year-over-year to -$294.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$406.0 million (down 108.07% YoY) and the FY2025 annual result came in at $7.2 billion, up 253.58% from the prior year.
- Non Operating Income advanced to -$294.0 million in Q1 2026 per JNJ's latest filing, from -$483.0 million in the prior quarter.
- The five-year high for Non Operating Income was $7.3 billion in Q1 2025, with the low at -$6.9 billion in Q2 2023.
- Average Non Operating Income over 5 years is -$302.4 million, with a median of -$273.0 million recorded in 2022.
- Year-over-year, Non Operating Income tumbled 6903.92% in 2023 and soared 404.53% in 2025.
- Johnson & Johnson's Non Operating Income stood at -$226.0 million in 2022, then surged by 286.28% to $421.0 million in 2023, then sank by 61.76% to $161.0 million in 2024, then sank by 400.0% to -$483.0 million in 2025, then surged by 39.13% to -$294.0 million in 2026.
- Business Quant data shows JNJ's Non Operating Income at -$294.0 million in Q1 2026, -$483.0 million in Q4 2025, and $478.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -294.00 Mn |
| Dec 28, 2025 | -483.00 Mn |
| Sep 28, 2025 | 478.00 Mn |
| Jun 29, 2025 | -107.00 Mn |
| Mar 30, 2025 | 7.32 Bn |
| Dec 29, 2024 | 161.00 Mn |
| Sep 29, 2024 | -1.80 Bn |
| Jun 30, 2024 | -653.00 Mn |
| Mar 31, 2024 | -2.40 Bn |
| Dec 31, 2023 | 421.00 Mn |
| Oct 1, 2023 | -499.00 Mn |
| Jul 2, 2023 | 384.00 Mn |
| Apr 2, 2023 | -6.94 Bn |
| Jan 1, 2023 | -330.00 Mn |
| Oct 2, 2022 | -226.00 Mn |
| Jul 3, 2022 | -273.00 Mn |
| Apr 3, 2022 | 102.00 Mn |
| Oct 3, 2021 | -1.85 Bn |
| Jul 4, 2021 | 488.00 Mn |
| Apr 4, 2021 | 882.00 Mn |